Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
globenewswire.com4basebio Announces Appointment of Chief Financial Officer and Board Changesglobenewswire.comMay 14
globenewswire.comMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updatesglobenewswire.comMay 12
globenewswire.comMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updatesglobenewswire.comMay 12
globenewswire.comClass Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join – Contact Levi & Korsinskyglobenewswire.comApr 6
globenewswire.comMREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREOglobenewswire.comApr 6